• FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

    Originally published by our sister publication Clinical Oncology NewsBy CONC StaffThe FDA has approved daraxonrasib (Rasonque, Revolution Medicines) for the treatment of adults with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.The once-daily pill is a RAS(ON) multi-selective, tri-complex inhibitor that roughly doubled overall survival (OS) in patients with previously treated metastatic pancreatic duct
  • Safety Groups Sound Alarm After FDA Compounding Panel Backs 6 of 7 Peptides

    Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Atrom, Piya W. - Stock.adobe.com.By Gina ShawThe FDA Pharmacy Compounding

Follow @newsl_pharmacy on Twitter!